Abstract:Impaired glucose uptake/utilization and impaired insulin signaling are the metabolic features of type 2 diabetes mellitus (T2DM) and Alzheimer's Disease (AD). Some studies proposed that AD is type 3 diabetes. Dulaglutide, a novel weekly administered long-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is an incretin mimetic approved for type 2 diabetes mellitus treatment. Although studies also demonstrated other GLP-1receptor agonists (e.g. Exendin-4) have neurotrophic/protective activity in cellular and animal models of stroke, Alzheimer's and Parkinson's diseases, it's the first time to observe effects of dulaglutide on the treatment of AD in the world. The study is to explore the protective effects and mechanism of dulaglutide on the learning and memory impairment induced by STZ intraventricular injection in non-transgenic mice. The male 13 weeks icv-STZ C57BL6 mice were divided into four groups (n=5 each group) administrated by dulaglutide with or without GLP-1 receptor inhibitor Exenatide 9-39 (Ex9-39) for 4 weeks: (A) treated with saline; (B) dulaglutide (0.24mg/kg/w,ip.); (C) dulaglutide and Ex9-39; wild icv-saline C57BL6 mice served as blank control. Western blotting was used to detect the levels of phosphorylated Tau, neurofilaments (NFs) protein, phosphorylated PI3K/Akt/GSK-3β signaling pathway. ELISA was used to detect the effects of the deposit of Aβ42. Morris water maze (MWM) was assessed the spatial learning and memory ability. The weekly intraperitoneal injection of dulaglutide decreased the high levels of hyperphosphorylated tau and NFs in STZ mice, and improved the phosphorylation of PI3K/Akt/GSK-3β signaling pathway. Dulaglutide also significantly decreased the deposit of Aβ42 of STZ mice, shortening the escape latency and increasing the number of hidden platform crossings in MWM task, whereas dulaglutide did not significantly affect the body weight and fasting blood glucose in mice. The effects of dulaglutide on decreasing the hyperphosphorylation of tau and neurofilaments proteins through improving the PI3K/Akt/GSK-3β signaling pathway, and reducing level of Aβ42 may be related to its protective effects on impairment of AD-like learning and memory.

Tirzepatide shows neuroprotective effects via regulating brain glucose metabolism in APP/PS1 mice

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats

Tirzepatide prevents neurodegeneration through multiple molecular pathways

Metformin Attenuates Plaque-Associated Tau Pathology and Reduces Amyloid-Β Burden in APP/PS1 Mice

Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice

P1‐181: DULAGLUTIDE IMPROVES LEARNING AND MEMORY IMPAIRMENT, HYPERPHOSPHORYLATED TAU AND NEUROFILAMENTS IN THE APP/PS1/TAU TRIPLE TRANSGENIC MICE

A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease

Metformin Treatment Attenuates Tau Seeding in Neuritic Plaques

DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling.

Intranasal 15D-Pgj2 Ameliorates Brain Glucose Hypometabolism Via PPAR-dependent Activation of PGC-1/GLUT4 Signalling in APP/PS1 Transgenic Mice

Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice

Intranasal 15d-PGJ2 ameliorates brain glucose hypometabolism via PPARγ-dependent activation of PGC-1α/GLUT4 signalling in APP/PS1 transgenic mice

The role of GLP-1/GIP receptor agonists in Alzheimer's disease

Subcutaneous Administration of Liraglutide Ameliorates Learning and Memory Impairment by Modulating Tau Hyperphosphorylation Via the Glycogen Synthase Kinase-3Β Pathway in an Amyloid Β Protein Induced Alzheimer Disease Mouse Model

A novel DPP ‐4 inhibitor Gramcyclin A attenuates cognitive deficits in APP / PS1 /tau triple transgenic mice via enhancing brain GLP ‐1‐dependent glucose uptake

Geniposide attenuates insulin-deficiency-induced acceleration of β-amyloidosis in an APP/PS1 transgenic model of Alzheimer's disease.

[Jiaotaiwan improves brain glucose metabolism in a mouse model of Alzheimer's disease by activating the PI3K/AKT signaling pathway]

Subcutaneous Liraglutide Ameliorates Methylglyoxal-Induced Alzheimer-like Tau Pathology and Cognitive Impairment by Modulating Tau Hyperphosphorylation and Glycogen Synthase Kinase-3Β.

GlyT1 Inhibition by NFPS Promotes Neuroprotection in Amyloid-β-Induced Alzheimer's Disease Animal Model

Increasing brain glucose uptake by Gypenoside LXXV ameliorates cognitive deficits in a mouse model of diabetic Alzheimer's disease

GLP-1 improves the neuronal supportive ability of astrocytes in Alzheimer's disease by regulating mitochondrial dysfunction via the cAMP/PKA pathway.